Prime Capital Investment Advisors LLC Makes New $35,000 Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Prime Capital Investment Advisors LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,088 shares of the biotechnology company’s stock, valued at approximately $35,000.

Other hedge funds also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Aldeyra Therapeutics during the second quarter worth about $32,000. Tower Research Capital LLC TRC boosted its stake in shares of Aldeyra Therapeutics by 47,866.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 4,308 shares during the period. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter valued at approximately $39,000. Cubist Systematic Strategies LLC purchased a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $57,000. Finally, UBS Group AG boosted its stake in shares of Aldeyra Therapeutics by 256.0% in the first quarter. UBS Group AG now owns 6,408 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 4,608 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Down 3.4 %

Shares of Aldeyra Therapeutics stock opened at $4.25 on Monday. Aldeyra Therapeutics, Inc has a 52-week low of $1.42 and a 52-week high of $11.97. The company has a 50 day moving average of $3.51 and a 200 day moving average of $3.31. The company has a market capitalization of $250.31 million, a P/E ratio of -6.64 and a beta of 1.51.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. As a group, research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the sale, the chief executive officer now owns 1,556,622 shares of the company’s stock, valued at $5,090,153.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Perceptive Advisors Llc acquired 37,712 shares of the business’s stock in a transaction on Friday, April 5th. The shares were bought at an average price of $4.74 per share, with a total value of $178,754.88. Following the completion of the acquisition, the insider now owns 9,275,851 shares in the company, valued at $43,967,533.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd C. Brady sold 97,914 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the sale, the chief executive officer now directly owns 1,556,622 shares in the company, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. Insiders bought 355,933 shares of company stock worth $1,473,245 over the last 90 days. 7.30% of the stock is owned by insiders.

Analyst Ratings Changes

ALDX has been the subject of several recent research reports. StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 29th. Oppenheimer raised shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, April 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.